GT Biopharma, Inc. (OTCMKTS: GTBP) had a great day in the market yesterday and I’m expecting that the positive movement will continue. The gains came after the company announced an update with regard to its COVID-19 development program. Here’s what’s going on:
GTBP Stock Gains On COVID-19 Update
In the press release, GT Biopharma provided an update with regard to the development of its TriKE technology as a potential treatment option for patients with severe COVID-19 infection. The company’s TriKE COVID-19 therapeutic is designed to seek and kill Novel Coronavirus 2019 virus infected cells prior to the release of additional virus particles from those infected cells.
Importantly, TriKE is an immune therapeutic, ultimately directing the body’s innate immune system to send Natural Killer cells to target distressed cells. By targeting and eliminating these cells before they have time to shed additional particles, the immunotherapy has the potential to eliminate coronavirus in patients.
Importantly, GT Biopharma partnered with Cytovance Biologics, a large United States-based contract development and manufacturing company. Under the terms of the agreement, Cytovance will provide drug development services to GT Biopharma in an effort to assist with bringing the TriKE product to market.
Importantly, the TriKE developed by GTBP targets the ACE2 receptor, which is believed to be the main host cell receptor targeted by the Novel Coronavirus.
In a statement, Anthony Cataldo, CEO and Chairman at GTBP, ahd the following to offer:
“Development is continuing according to plan, and we are working to prepare TriKE COVID-19 for further preclinical testing and GMP manufacturing. We are pleased with the progress Cytovance is making, and are looking forward to being able to evaluate the TriKE COVID-19 therapeutic in humans.”
This News Is Huge
The news released by GT Biopharma proved to be overwhelmingly positive. Not only does the company have a candidate under development for the treatment of severe COVID-19 symptoms, development is going well.
Ultimately, this represents a massive opportunity.
While several companies are working on vaccines, there are few companies that actually have a tangible COVID-19 treatment option under development. Moreover, there is likely to be a long-term need for treatment.
The fact of the matter is that the coronavirus that causes COVID-19 is a cousin of the coronavirus that causes the common cold. If it were easy to create effective vaccines for this class of viruses, we’d already have one for the common cold.
So, while there are plenty of companies working toward a vaccine, there is a strong argument that a vaccine would lack the level of efficacy needed to eradicate COVID-19 completely. As such, it is likely that COVID-19 will continue to pop up year after year ahead.
However, this wouldn’t be such a scary idea if there were a cure for those who do fall critically ill with the condition. GTBP is making strong progress developing that treatment. Ultimately, there’s incredible value in that, making this stock one to watch closely.
Get Free Alerts
Join our free mailing list to receive stock alerts!
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and GT Biopharma, CNA Finance has been hired for a period beginning on 3/1/20 and ending on 4/31/20 to conduct digital advertising and marketing and publicly disseminate information about GTBP via Websites and Email. We have an agreement and have been paid fifteen thousand dollars via bank wire transfer to cover the cost of content production. The agreement was extended on May 25 and will run through June 24, 2020. For this extension, GTBP paid CNA Finance an additional fifteen thousand dollars. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and GT Biopharma has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.